BioPharma Dive9h
Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
Eli Lilly’s (LLY) Alzheimer’s Drug Is Rejected in Europe Over Safety Fears
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval
The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain ...
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
Eli Lilly's Alzheimer's drug rejected in Europe
The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...
STAT14h
Eli Lilly’s Alzheimer’s drug gets thumbs-down from European regulators
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say it shouldn't be approved.
EU regulator rejects Eli Lilly's Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...
Eli Lilly fails to win EU backing for Alzheimer’s therapy
Eli Lilly (LLY) stock in focus as an expert panel of the EU drug regulator declines to endorse its Alzheimer's drug Kisunla.